Latest Quarterly Updates
Antitrust & Competition Life Sciences Quarterly Update Q3 2023
The FTC abandoned its pursuit of a novel theory and settled its Amgen/Horizon lawsuit 10 days before the scheduled preliminary injunction hearing. The FTC continues to explore other novel theories in its ongoing investigation of the Pfizer/Seagen transaction. The FTC remains concerned with “killer acquisitions” — transactions where Big Pharma with a commercial or late-stage asset acquire a clinical- or preclinical-stage asset allegedly with the purpose of eliminating or avoiding future competition. A new trade group formed that is specifically focused on the FTC’s life science antitrust enforcement.

Antitrust & Competition Healthcare Quarterly Update Q3 2023
Private equity roll-up and serial acquisition practices are under heightened scrutiny as the FTC backed up its recent rhetoric by challenging Welsh Carson’s roll-up of anesthesia practices in Texas. California published draft regulations outlining pre-notification requirements for healthcare transactions that will require additional information and extend closing timelines. These regulations specifically reference private equity roll-up transactions and appear to be part of an ongoing effort, in line with the FTC’s actions, to scrutinize private equity firms’ activity in the healthcare space.

Antitrust & Competition Technology Quarterly Update Q2 2023
Antitrust enforcers remained active across the globe, with the announcement by the FTC and DOJ of proposed guidelines that have an emphasis on tech mergers in the United States, and several investigations of major tech deals moving toward resolution (or continuing) in the United States, Europe, and elsewhere.

Learn more
Visit our Antitrust & Competition page for details about how we help clients with merger clearance, complex litigation, as well as provide counsel on operational business issues.

Archive
- Antitrust & Competition Technology Quarterly Update Q2 2023
- Antitrust & Competition Technology Quarterly Update Q1 2023
- Antitrust & Competition Technology 2022 Year in Review
- Antitrust & Competition Technology Quarterly Update Q3 2022
- Antitrust & Competition Technology Quarterly Update Q2 2022
- Antitrust & Competition Technology Quarterly Update Q1 2022
- Antitrust & Competition Life Sciences Quarterly Update Q2 2023
- Antitrust & Competition Life Sciences Quarterly Update Q1 2023
- Antitrust & Competition Life Sciences 2022 Year In Review
- Antitrust & Competition Life Sciences Quarterly Update Q3 2022
- Antitrust & Competition Life Sciences Quarterly Update Q2 2022
- Antitrust & Competition Life Sciences Quarterly Update Q1 2022
Connect With Our Team
- /en/people/l/lacy-andrew
Andrew Lacy
PartnerCo-Chair, Antitrust + Competition - /en/people/o/oruc-arman
Arman Oruc
PartnerCo-Chair, Antitrust + Competition - /en/people/j/jordan-sarah
Sarah Jordan
Partner - /en/people/s/silver-elliot
Elliot Silver
Partner - /en/people/b/ben-aharon-ortal
Ortal Ben Aharon
Associate